Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

University of Cambridge-led trial shows significant improvement in outcomes for inherited, aggressive forms of breast cancerA ...

Karen Eubanks Jackson has reshaped the conversation around breast cancer for Black women in America—and now, with the ASCO ...

Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...